Summary. Postthrombotic syndrome (PTS) is a chronic complication of deep vein thrombosis (DVT) that develops in 20-50% of patients. PTS manifests as a spectrum of symptoms and signs of chronic venous insufficiency that can impose significant morbidity and have a negative impact on quality of life. Chronic venous hypertension caused by a combination of residual venous obstruction and valvular reflux is believed to play a major role in the pathophysiology of PTS. The Villalta scale is the most widely applied clinical scale used to diagnose and define PTS. Proximal DVT and recurrent ipsilateral DVT are the two principal established risk factors for PTS, and efforts in recent years have been focused on identifying a combination of clinical and biomarker predictors that will define high-risk patients and possibly new therapeutic targets. The best way to prevent PTS is to prevent the occurrence of DVT, and to provide optimal anticoagulation for the acute phase of DVT once it occurs. Recent years have brought progress in our understanding of the role of endovascular techniques in the prevention and treatment of PTS and the subgroups of patients that may benefit from these modalities. Pharmacomechanical catheter-directed thrombolysis is the most promising interventional modality for prevention of PTS. This review summarizes the current state of evidence on PTS of the lower limbs, and highlights areas where uncertainty still exists that require further research.
Introduction
Postthrombotic syndrome (PTS) is a chronic complication of deep vein thrombosis (DVT) that develops in 20-50% of patients following a DVT in the leg despite treatment with anticoagulation, and is severe in 5-10% of cases [1] [2] [3] . Symptoms of PTS usually occur within 3-6 months after DVT, but can occur up to 2 years after DVT [4] .
The overall estimated incidence of venous thromboembolism (VTE) is 0.7-2 per 1000 person-years, and increases with age [5, 6] . The prevalence of PTS in the population is expected to increase as the number of adults with VTE continues to grow [7] .
PTS manifests as a spectrum of symptoms and signs of chronic venous insufficiency [1] [2] [3] . Manifestations of PTS range from mild symptoms to debilitating complaints that impose significant morbidity and have a negative impact on quality of life (QOL) [8] . DVT patients with PTS have poorer QOL than DVT patients without PTS [8, 9] , and scores worsen as the severity of PTS increases [9] . PTS is a costly condition. In 2006 in the USA, the annualized median total cost for DVT patients who developed PTS was $20 569, as compared with $15 843 in matched controls with DVT and no PTS [10] . This cost increase was attributable to greater outpatient resource utilization, such as imaging, laboratory and pathology testing, hospital admissions, and pharmacy claims.
Because treatment options for PTS are limited, its management mainly relies on the prevention of its occurrence after DVT. The first evidence-based guidelines focused solely on PTS were published by the American Heart Association in 2014 [3] .
This review summarizes recent advances in our knowledge, focusing on PTS of the lower limbs.
Diagnosis
There is no gold standard laboratory, imaging or functional test that establishes the diagnosis of PTS. PTS is primarily diagnosed on clinical grounds, according to the presence of typical symptoms and signs in a patient with previous DVT. In some patients, it can take a few months for the initial pain and swelling associated with acute DVT to resolve, so a diagnosis of PTS should be deferred until after the acute phase (3-6 months) [11] .
Typical symptoms and signs of PTS are shown in Table 1 and Fig. 1 . Symptoms differ from patient to patient, may be intermittent or persistent, usually worsen by the end of the day or with prolonged standing or walking, and improve with rest or limb elevation. Signs of PTS can also vary in severity (Table 1) .
A number of clinical scales have been used to diagnose and define PTS. Of these, three were developed specifically for PTS: the Villalta scale, the Ginsberg measure, and the Brandjes scale. The others, developed for chronic venous disease, include the clinical, etiologic, anatomic and pathophysiologic classification (CEAP), the Venous Clinical Severity Score, and the Widmer scale [3] . Of these, the Villalta scale is the most widely applied, and was recommended by the ISTH in 2009 [12] . The Villalta scale is a clinical measure that incorporates the assessment of five subjective (patient-rated) venous symptoms and six objective (clinician-rated) venous signs, as well as the presence or absence of ulcer, in the DVT-affected leg ( Table 2 ). The Villalta scale has been shown to be valid, reproducible, and responsive to clinical change, and shows good correlation with generic and disease-specific QOL scores [8, 10] , and with anatomic and physiologic markers of PTS [13] . Diagnosis of PTS with the Villalta scale requires a clinical visit to perform a physical examination of the affected limb. Utne et al. recently developed and validated a self-administered visually assisted tool for patient reporting of leg symptoms and signs as a means to assess PTS; it includes comprehensive explanatory text and a visual guide to all elements of the Villalta scale and their grading. The sensitivity and specificity of this tool for PTS were 98% and 83%, respectively [14] .
In the absence of clinical features of PTS in a patient with previous DVT, demonstrating the presence of venous The patient has venous claudication, swelling, bluish discoloration, and pigment changes of the left lower extremity. His Villalta score is 16 [3] . [Color figure can be viewed at wileyonlinelibrary.com]. 
Each symptom is self-rated by the patient, and each clinical sign is rated by the clinician as 0 (absent), 1 (mild), 2 (moderate), or 3 (severe), except ulcer, which is marked as present or absent. All numeric points are summed to yield a total score: a score of 0-4 indicates the absence of PTS, and a score of ≥ 5 indicates PTS (5-9, mild PTS; 10 -14, moderate PTS; and > 14 or the presence of an ulcer, severe PTS). The [18] . The use of APG in chronic deep venous obstructive disease remains debatable [19] .
Ascending venography is an invasive method of obtaining a panoramic view of lower-limb venous outflow in the infrainguinal area. Ambulatory venous pressure (AVP) provides an overall assessment of venous dysfunction [20] . AVP is maximal in limbs having venous obstruction with reflux. Intravascular ultrasound (IVUS) can provide better images of iliac vein and inferior vena cava thrombi [21] . IVUS may be helpful in conjunction with venography in detecting chronic obstructive pathologies. We emphasize that these tests are typically only applied when endovascular recanalization is being considered, and can be useful in determining the extent of venous involvement, the presence of collaterals, and the best potential site of entry into the venous system.
Pathophysiology
The pathophysiology of PTS remains incompletely understood; however, it is thought that the absence of a pressure decrease in the venous system of the lower limbs during walking (i.e. increased AVP) plays a central role [21] . Increased AVP leads to impaired venous return, reduced calf muscle perfusion, abnormal function of the microvasculature with increased tissue permeability, and, consequently, the characteristic clinical manifestations of PTS [22] . DVT can lead to chronic venous hypertension via two principal mechanisms: persistent (residual) venous obstruction (RVO) and valvular reflux. After DVT, recanalization of the thrombosed veins, which occurs through a combination of fibrinolysis, thrombus organization, and neovascularization, is often incomplete, resulting in RVO [23] . Damage to venous valves leading to valvular reflux probably occurs by thrombus-induced activation of inflammation, fibrous scarring associated with acute and resolving thrombosis, or venous dilation distal to the obstructed venous segment [24] . These findings provide the basis of the 'open vein hypothesis', which postulates that early thrombus elimination and restoration of venous flow might prevent PTS after proximal DVT.
Inflammation may play a role in promoting the development of PTS by delaying thrombus resolution and by inducing vein wall fibrosis, which promotes valvular reflux [25, 26] . In the first step, the thrombus and vein wall are invaded by leukocytes that, secreting growth factors, proteases, and cytokines, contribute to thrombus resolution. Cytokines and growth factors are involved in neovascularization, and promote further leukocyte influx [27, 28] At the interface between the thrombus and vein wall, activated inflammatory cells and platelets interact. Activated neutrophils release nuclear material called neutrophil extracellular traps (NETs). Studies have demonstrated that, if NET formation is inhibited or destabilized, thrombus formation is lessened, suggesting their importance [29, 30] . In the second step, proteolytic enzymes and free radicals released by leukocytes damage venous valves and inactivate fibrinolysis, leading to residual thrombosis and progressive fibrosis [25, 31] . The intense inflammatory response following DVT is favored by activation of matrix metalloproteinases (MMPs), which alter the extracellular matrix. The activity of MMPs is controlled by tissue inhibitors of MMPs (TIMPs), and an imbalance between MMPs and TIMPs may contribute to the development of PTS, influencing tissue remodeling, endothelial dysfunctional activation, and vessel recanalization [25, [32] [33] [34] [35] . There may also be a genetic predisposition to the development of PTS resulting from gene polymorphisms associated with vein wall remodeling [36] .
Risk factors
Because the risk factors for PTS are incompletely understood, it is difficult to predict which patients with DVT will develop PTS. Improving our understanding of the risk factors that promote the development of PTS after DVT is an important initial step towards the eventual goal of developing effective management strategies for PTS. Table 3 summarizes established and presumed risk factors according to time points after DVT diagnosis.
Older age increases the risk of PTS from 30% to threefold [1, [37] [38] [39] . Obesity (body mass index of > 30) more than doubles the risk of PTS [1, 2, [38] [39] [40] . Pre-existing primary venous insufficiency increases the risk of PTS up to two-fold [2, 16, 38] . The risk of PTS is two-fold to threefold higher after proximal (especially with involvement of the iliac or common femoral vein) than distal (calf) DVT [41, 42] . A history of DVT increases the risk up to 630% [37] [38] [39] [40] [41] [42] .
Whether DVT was unprovoked or secondary (e.g. resulting from recent surgery, trauma, immobilization, or active cancer) does not appear to influence the risk of developing PTS [38, 40, 43, 44] . Gender and inherited thrombophilia have no consistent relationship with PTS [2, 3, 38, 40, 43, 45] .
The risk of PTS increases if the level of anticoagulation is inadequate during the first 3 months of treatment with vitamin K antagonists (VKAs). Two studies have demonstrated that a subtherapeutic International Normalized Ratio (INR) during the first 3 months of therapy increases the risk of PTS. The first study reported that patients whose INR was subtherapeutic for > 50% of the time had a 2.7-fold higher risk of PTS [39] , whereas the second found an odds ratio (OR) of 1.84 (95% confidence interval [CI] 1.13-3.01) for PTS in patients whose INR was subtherapeutic for > 20% of the time [46] .
Among anticoagulants, effectiveness in preventing PTS could differ. Pooled analyses of randomized controlled trials (RCTs) that compared extended low molecular weight heparin (LMWH) with VKAs for the treatment of DVT reported a lower rate of PTS (OR 0.77; 95% CI 0.67-0.90) and a lower incidence of venous ulcers (relative risk [RR] 0.13; 95% CI 0.02-0.71) with LMWH [47] . The main hypothesis to explain this finding is the presumed anti-inflammatory properties of LMWH. The risk of PTS in DVT patients treated with direct oral anticoagulants (DOACs) is unknown. Because of their more predictable anticoagulant response, DOACs could decrease the risk of PTS as compared with VKAs [48] . In a recently published post hoc analysis of a subpopulation of the Einstein DVT trial, the cumulative PTS incidence rates at 60 months of follow-up were 29% in the rivaroxaban group and 40% in the enoxaparin/VKA group; however, this difference did not reach statistical significance (hazard ratio [HR] of PTS development for rivaroxaban was 0.76 [95% CI 0.51-1.13]) [49] . Additional studies are needed to test this possibility.
The total duration of anticoagulation does not appear to influence the risk of PTS. In a multicenter trial comparing 6 weeks and 6 months of warfarin treatment, the risk of PTS was similar in both groups [37] . Similarly, Stain et al. observed that duration of VKA therapy (< 6, 6-12 or > 12 months) did not influence the risk of PTS [40] .
Recurrent ipsilateral DVT increases the risk of PTS by four-fold to six-fold, presumably by damaging compromised venous valves or aggravating venous outflow obstruction [1, 39, 43, 50] .
Persistent venous symptoms/signs 1 month after acute DVT increase the risk of subsequent PTS [1] .
Conflicting evidence exists regarding the relative role of RVO and/or valvular reflux on CUS as predictors of PTS. Prandoni [51] . Sartori et al. recently showed that the degree and extension of RVO after 3 months of VKA treatment is an early marker of PTS [52] , and this finding was corroborated by a large study from Prandoni et al. that showed, in 869 patients with acute proximal DVT, that RVO is not only likely to play an independent role in the late occurrence of PTS (HR 2.34; 95% CI 1.87-2.93), but also predicts recurrent VTE, cancer, and arterial thrombotic events [53] . However, controversy remains, as Haenen et al. showed reflux in the proximal deep veins, rather than RVO, to be associated with worse CEAP scores [54] . In a second study, the same group showed superficial venous reflux to be the most important risk factor for onset of PTS symptoms, and 64% of patients with severe PTS were shown to have a combination of superficial and deep reflux [55] . Yamaki et al. reported that the presence of reflux, as reflected by elevated peak reflux velocity in proximal veins, was an independent predictor of advanced signs of PTS. The proportion of patients with RVO was reported to be similar in patients with CEAP scores of C0-3 and C4-6 [56] . Finally, in a study of 114 patients followed by ultrasound and air plethysmography, four factors were identified as best predictors of PTS: extensive clot load on presentation; < 50% clot regression at 6 months; venous filling index of > 2.5 mL s À1 ; and abnormal outflow rate (< 0.6) [57] . The sonographic and biochemical properties of the initial or residual clot may prove to have a future role in predicting PTS, as several preliminary studies have attempted to characterize a sonographic and biochemical thrombus pattern that is most associated with PTS development [58] [59] [60] .
Some inflammatory markers, such as C-reactive protein, interleukin (IL)-6, IL-8, IL-10, and Intercellular adhesion molecule (ICAM)-1, have been found to be associated with the onset of PTS [26, 35, 61, 62] . However, in a systematic review including 10 studies that analyzed the association between biomarkers of inflammation and PTS in DVT patients, we could not find sufficient evidence to come to a conclusion on the importance of inflammation in the development of PTS. Meta-analysis was not possible, owing to the high heterogeneity among studies in terms of populations included, exclusion criteria, timing after DVT and methods used for biomarker measurement, and statistical measures of association between biomarkers and PTS [63] .
In a recent cohort study, patients with PTS showed higher levels of MMP-1 and MMP-8 during the acute phase of DVT compared to patients without PTS [64] . MMP-1 and MMP-8 may be markers of fibrosis during the inflammatory process, and further studies are indicated to determine their role as potential biomarkers for PTS.
D-dimer levels reflect chronic thrombus or ongoing activation of coagulation. Whether D-dimer might be a useful marker to predict the development of PTS after DVT is not yet known. A systematic review included 11 studies published until 2013 that investigated the association between D-dimer and PTS [65] . The majority of studies suggested an increased risk of PTS (statistically significant in four of them) with higher D-dimer levels; however, no firm conclusion could be reached, owing to heterogeneity between studies regarding method, cutoff points for positivity, timing of D-dimer measurement, and the definition of PTS. Two recent studies [52, 66] did not demonstrate an association between D-dimer and PTS.
Coagulation factor VIII has also been studied as a potential marker for PTS. A systematic review summarized four studies that evaluated FVIII levels in association with PTS [45] . Results were not combined, mainly because of different time points of measurement after DVT. No statistically significant difference in FVIII activity was found between PTS-positive and PTS-negative patients in three of them. The same conclusion was reached in two recent studies [52, 67] . In contrast, Roberts et al. [66] found FVIII levels at 6 months post-DVT to be significantly associated with PTS.
Prevention
The best way to prevent PTS is to prevent the occurrence of DVT. Therefore, the use of pharmacologic or mechanical thromboprophylaxis to prevent VTE in high-risk patients and settings, as recommended in evidence-based consensus guidelines, is strongly suggested [44, 68, 69] . As ipsilateral DVT recurrence is an important risk factor for PTS, preventing recurrent DVT by providing optimal anticoagulation of appropriate intensity and duration for the initial DVT is a key goal [70] . The observation that the risk of PTS is associated with poor early control of anticoagulation strengthens this recommendation.
Elastic compression stockings (ECSs), by reducing edema and venous hypertension, could play a role in preventing PTS. However, there are conflicting data on their long-term effectiveness in preventing PTS. Two small, randomized, open-label trials reported that wearing 30-40 mmHg knee-high ECSs for at least 2 years after proximal DVT was effective in preventing PTS [43, 71] . However, a recent large (n = 803), multicenter, randomized, placebo-controlled trial showed no evidence of benefit of 30-40 mmHg graduated ECSs, worn for 2 years after proximal DVT, in preventing PTS: rates of PTS, rates of recurrent VTE and QOL scores were similar in the active and placebo stockings groups [72] . Although this is the largest and only placebo-controlled study to date to assess the effectiveness of ECSs for prevention of PTS, results have been critiqued, mainly regarding adherence to study stockings, which, although similar in both groups, diminished over follow-up. A recent systematic review and meta-analysis included five RCTs (n = 1418). The HR for PTS with ECS was 0.69 (95% CI 0.47-1.02). It is of note that the strength of compression stockings in these studies differed: one study did not report stockings strength; the strengths in the others were 26-36 mmHg (one study), 21-40 mmHg (one study), 20-30 mmHg (one study), and 30-40 mmHg (two studies). Owing to heterogeneity and the inclusion of unblinded studies with a high risk of bias, this estimate should be interpreted with caution [73] . On the basis of these data, the latest guideline statements do not support the routine use of ECSs to prevent PTS [3, 70] . Nevertheless, ECSs are unlikely to cause harm, so a trial of below-knee ECSs for patients who have residual leg swelling or discomfort after proximal or distal DVT is recommended [3, 70] . In this context, the results of the OCTAVIA trial were recently reported. This was a non-inferiority study of 518 patients free of PTS, who were randomized 1 year after diagnosis of proximal DVT to stop or continue using ECSs for another year. Among these, 28% of patients had been treated with 23-32 mmHg graduated stockings, and the rest with 34-46 mmHg ECSs. The incidence rates of PTS were 19.9% (95% CI 16-24%) in the stop-ECS group and 13.0% (95% CI 9.9-17%) in the continue-ECS group, giving an absolute difference of 6.9% (95% CI upper limit of 12.3%). Stopping ECS use after 1 year seemed to be not non-inferior to continuing ECS use for a total of 2 years. ECS class was not associated with the occurrence of PTS, and adjustment for ECS class did not change the secondary endpoints, including QOL. Selection of patients might have influenced these findings, as only patients who were highly compliant with ECS use during the first year after DVT were included. In addition, the lack of a placebo control may have influenced patient reporting of symptoms. Nevertheless, the findings suggest that, in selected patients, compression might still be an important management strategy, even 1 year after DVT [74] .
Patients with iliofemoral DVT have 2-year PTS rates of ≥ 50%, despite anticoagulation [75] . These patients are also more likely to develop severe PTS manifestations, such as disabling venous claudication and venous ulcers [76] . Early clot removal can prevent persistent venous obstruction and damage to the vein valves, both of which are important causes of secondary venous hypertension [77] [78] [79] . Catheter-directed thrombolysis (CDT) refers to the direct intrathrombus administration of a fibrinolytic drug via a catheter embedded within the thrombus using imaging guidance. Successful lysis of the thrombus is expected in 80-90% of patients with DVT symptom duration of < 14 days [77] [78] [79] [80] . The theoretical advantages of intrathrombus infusion versus systemic thrombolysis include: enhanced clot removal efficacy by the ability to achieve a high intrathrombus drug concentration; reduced thrombolytic drug dose, treatment time, hospital resource use, and bleeding complications; and that catheter access into the venous system may enable treatment of underlying venous anatomic abnormalities, which may help to reduce the risk of recurrent DVT [81] . So far, the Catheter-directed Venous Thrombolysis (CaVenT study) is the only multicenter RCT to evaluate the long-term outcome of additional CDT as compared with standard treatment in patients with a proximal femoral or iliac vein thrombosis. At 2 years, patients treated with CDT showed an absolute reduced frequency of PTS of 14.4% (95% CI 0.2-27.9%) at the cost of an additional 3% rate of major bleeding [75] . Additionally, CDT improved patency of the veins and prevented reflux. In a recent report, the 5-year follow-up of CaVenT patients showed a persistent benefit of CDT in reducing PTS after extensive DVT [82] . The absolute risk reduction of 14% after 2 years increased to 28% after 5 years, and the number needed to treat decreased from seven to four. After 5 years, there was still a reduction in reflux in the CDT group (22% risk reduction as compared with the control group), but no difference in vein patency between the groups. However, 41% of CDT patients still developed PTS by 2 years, indicating that CDT does not eliminate the risk of PTS, and CDT did not result in improved QOL at 2 years or at 5 years of follow-up.
A number of methods have been developed to enable faster delivery and intrathrombus dispersion of the fibrinolytic drug. Ultrasound-assisted CDT involves the delivery of the fibrinolytic drug through a specialized catheter that also emits low-power ultrasound energy into the thrombus. However, a randomized trial and a retrospective comparative study did not find an added benefit of the ultrasound catheter as compared with standard CDT [83, 84] .
Pharmacomechanical CDT (PCDT) involves the use of catheter-mounted thrombectomy devices along with intrathrombus delivery of fibrinolytic drugs. Retrospective studies found that the safety and efficacy of PCDT is at least as good as infusion-only CDT, with 3-5% rates of major bleeding, 40-50% reductions in drug dose and treatment time as compared with infusion-only CDT, and markedly reduced length of hospital stay and intensive care unit utilization [85] [86] [87] . Although, as yet, there are no completed, high-quality RCTs evaluating PCDT, the ATTRACT Study (NCT00790335) and CAVA trial (NCT00970619) will provide key evidence on the role of venous thrombolysis in the management of acute DVT.
Device-only percutaneous mechanical thrombectomy (PMT) (without the use of a fibrinolytic drug) for DVT has shown disappointing results. This method has not removed sufficient thrombus to be therapeutically useful, and can result in symptomatic pulmonary embolism. Hence, the use of PMT is strongly discouraged unless a patient with clinically severe DVT is felt to absolutely require therapy and fibrinolytic drugs cannot be given [88] .
Surgical thrombectomy might be considered in selected patients with extensive acute proximal DVT who are not candidates for CDT or PCDT because of bleeding risk. A meta-analysis of eight studies (n = 611) that addressed surgical thrombectomy versus anticoagulation for the prevention of PTS found that surgical thrombectomy was associated with a 33% RR reduction (95% CI 13-48%) in the incidence of PTS [89] . There have not been any studies comparing surgical thrombectomy with CDT/PCDT.
Thus, in the American Heart Association scientific statement on PTS, it is suggested that, in patients with extensive (e.g. iliofemoral) thrombosis with recent onset (i.e. ≤ 14 days) of symptoms, a low risk of bleeding, and a lifeexpectancy of at least 1 year, who are seen at hospital centers experienced in performing these techniques, CDT/PCDT with or without balloon angioplasty and stenting, or surgical thrombectomy in patients who are not candidates for PCDT/CDT, might be considered (Grade B for both) [3] . However, the 2016 CHEST Guideline for Antithrombotic Therapy for VTE Disease still suggest anticoagulant therapy alone over CDT (Grade 2C recommendation), as the balance of risks and benefits with CDT is uncertain, and the overall quality of evidence is still low [70] .
Treatment
Compression-based therapies, usually ECSs, are considered first-line treatment for PTS. Their use is based primarily on experience from patients with primary venous insufficiency, with the goal of symptom reduction and improvement of daily functioning [11] . If 20-30 mmHg ECSs do not adequately control symptoms, a 30-40 mmHg or 40-50 mmHg stocking can be tried. In patients with moderate to severe PTS whose symptoms are not adequately controlled with ECSs alone, the portable Venowave intermittent compression device can be tried. In a randomized crossover trial in 32 patients with severe PTS, wearing the device on the affected leg alone or in combination with ECSs was associated with improvement in QOL and reduced severity of PTS [90] . For patients with severe, intractable PTS, intermittent pneumatic compression sleeve units can be used to provide symptom relief [91] .
Venoactive drugs that have been considered for the treatment of PTS include rutosides (thought to reduce capillary filtration and microvascular permeability), defibrotide (downregulates plasminogen activator inhibitor-1 release and upregulates prostacyclin, prostaglandin E 2 , and thrombomodulin), and hidrosmin (mechanism of action unknown). A systematic review and meta-analysis of four randomized trials that evaluated the effectiveness of these drugs for PTS found low-quality evidence to support their use, as studies were limited by a high degree of inconsistency and imprecision. Furthermore, drug treatment was usually of short duration (e.g. 8 weeks to a few months), and potential long-term side effects are unknown. More rigorous studies are needed to assess the safety and effectiveness of pharmacologic treatments for PTS [92] .
The limited available data suggest that exercise may benefit patients with PTS. In a study of 30 patients with chronic venous insufficiency (half had prior DVT), a 6-month leg-strengthening exercise program led to improved calf muscle function and calf muscle strength [93] . In another study, a 6-month exercise training program reduced PTS severity and improved QOL, with no adverse events [94] .
Patients who have chronic iliac vein obstruction are especially susceptible to severe PTS that includes severe pain, venous claudication, uncontrolled edema, and/or venous ulcers. Venous ulcers markedly impair QOL, increase healthcare costs, predispose the patient to infection, and may require surgical therapy [11] . Patients with postthrombotic ulcers should be managed with a multidisciplinary team approach. The mainstay of treatment for venous ulcers is compression therapy. A Cochrane systematic review concluded that compression increases ulcer healing rates as compared with no compression. Multicomponent systems are more effective than single-component systems. Multicomponent systems containing an elastic bandage appear to be more effective than those composed mainly of inelastic constituents [95] . Other treatments include topical dressings and hemorheologic agents such as pentoxifylline, which increases microcirculatory blood flow and ischemic tissue oxygenation. A recent systematic review concluded that pentoxifylline (400 mg, three times daily) is currently the only drug for which there is promising evidence to support its use as adjunctive treatment for chronic venous ulcers [96] . Ulcers can be refractory to therapy, and often recur.
Although data from RCTs are currently lacking, case series and prospective cohort studies suggest that at least some subgroups of patients with PTS may benefit from the integration of endovascular therapy into the overall management strategy when conservative treatment fails [3] . Two components that are directly involved in causing the disability associated with PTS are amenable to endovascular correction: chronic iliac vein obstruction and saphenous vein reflux [81] . Preliminary studies suggest that image-guided, catheter-based endovascular therapy can eliminate iliac vein obstruction (with stent placement) and saphenous venous valvular reflux (with endovenous thermal ablation), and thereby reduce PTS severity and improve health-related QOL by healing ulcers and relieving symptoms [97, 98] . Stenting is generally accepted as the treatment for residual deep venous obstructions located between the common femoral vein and inferior vena cava. However, these interventions are associated with substantial risks and costs, and their effectiveness has not been prospectively validated. There is no consensus on the value of extending anticoagulation in patients with PTS beyond the durations recommended in consensus guidelines on management of DVT [70] . The use of anticoagulant and antiplatelet therapy postprocedure may differ among interventionists, with more aggressive use of antithrombotic therapy in patients who have received stents. The benefit-to-risk ratio of aspirin therapy is believed to be favorable for most patients receiving stents. The decision to continue postprocedure anticoagulation is dependent on multiple factors, including the presence of residual clot, a hypercoagulable state, and recurrence of thrombus [99, 100] . The National Heart Lung and Blood Institute has funded a planning grant for the development of the Chronic Venous ThrombosisRelief with Adjunctive Catheter-Based Therapy (CTRACT) Trial, which will aim to compare medical and endovascular strategies for PTS management [81] .
Conclusion
PTS is a frequent complication of DVT that has the potential to reduce QOL, leads to chronic functional disability, and poses difficult management challenges.
To date, in the absence of validated tools capable of predicting PTS, only the presence of extensive proximal DVT could lead to specific therapeutic approaches aimed at reducing PTS. The development of risk prediction indices to predict the risk of PTS at the time of DVT diagnosis, in order to help guide the long-term management of patients with DVT, is underway. Research aimed at improving our understanding of the pathophysiology of PTS and suggesting future therapeutic targets is also needed. As prevention of PTS by providing optimal anticoagulation currently represents the best strategy, studies focusing on assessment of the impact and cost-effectiveness of DOACs and extended LMWH therapy on the risk of PTS are needed. Finally, trials of the effectiveness, safety and costeffectiveness of PCDT to treat DVT as a means to prevent PTS, and evaluation of the safety and long-term effectiveness of endovascular and surgical procedures to treat severe PTS, are advocated. Table 4 summarizes ongoing studies on the prevention and treatment of PTS.
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